1. Schaus, J. M.; Audia, J. E.; Dressman, B. A.; Kaldor, S. W.; Krushinski, J. H.; Adham, N.; Benvenga, M. J.; Brancheck, T. A.; Calligaro, D. O.; Fuller, R. W.; Hemrick-Luecke, S. K.; Johnson, K. W.; Leander, J. D.; Lucaites, V. L.; Nelson, D. L. G.; Overshiner, C. C.; Phebus, L. A.; Roush, M. E.; Wainscott, D. B.; Wolff, M. C.; Zgombick, J. M. 8th Congress of the International Headache Society, Amsterdam, June 10–14, 1997
2. N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: A Potent, Selective, and Orally Active 5-HT1F Receptor Agonist Potentially Useful for Migraine Therapy
3. Mathes, B. M.; Johnson, K. W.; Nelson, D. L.; Phebus, L. A.; Schaus, J. M.; Wainscott, D. B.; Filla, S. A. Presented at the 220th National Meeting of the American Chemical Society. Washington, D. C. August 20–24, 2000; Paper MEDI 240.
4. Neurogenic Model of Migraine
5. A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation